# name
Long-term renal outcomes in ICI-associated acute interstitial nephritis: a comprehensive comparative study

# metadata.dc.description[].value
Comunicació/presentació a: 61st ERA Congress, The European Renal Association, Estocolm, 23-26 maig 2024

# metadata.dc.description.abstract[].value
Immune checkpoint inhibitors (ICI) have transformed cancer treatment, but they may lead to immune- mediated acute interstitial nephritis (ICI-AIN), in 2-5% of patients. About 35-40% show full kidney function recovery three months post ICI-AIN. Limited evidence exists for long-term renal toxicity.

# metadata.dc.relation.ispartof[].value
Nephrology Dialysis Transplantation, 2024, vol. 39, sup. 1, p. i668-i669

# metadata.dc.rights[].value
(c) Martinez Valenzuela, Laura et al., 2024

# metadata.dc.source[].value
Comunicacions a congressos (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
Long-term renal outcomes in ICI-associated acute interstitial nephritis: a comprehensive comparative study